Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 108

1.

Graves' disease and toxic nodular goiter are both associated with increased mortality but differ with respect to the cause of death: a Danish population-based register study.

Brandt F, Thvilum M, Almind D, Christensen K, Green A, Hegedüs L, Brix TH.

Thyroid. 2013 Apr;23(4):408-13. doi: 10.1089/thy.2012.0500. Epub 2013 Mar 18.

PMID:
23253072
2.

Increased Cardiovascular Mortality and Morbidity in Patients Treated for Toxic Nodular Goiter Compared to Graves' Disease and Nontoxic Goiter.

Giesecke P, Rosenqvist M, Frykman V, Friberg L, Wallin G, Höijer J, Lönn S, Törring O.

Thyroid. 2017 Jul;27(7):878-885. doi: 10.1089/thy.2017.0029. Epub 2017 Jun 5.

PMID:
28471268
3.

Hyperthyroid patients without Graves' orbitopathy are not at increased risk of developing glaucoma: a nationwide Danish register-based case-control study.

Brandt F, Thvilum M, Hegedüs L, Brix TH.

Endocrine. 2018 Jan;59(1):137-142. doi: 10.1007/s12020-017-1485-0. Epub 2017 Dec 2.

PMID:
29198022
4.

Mortality in Graves' orbitopathy is increased and influenced by gender, age and pre-existing morbidity: a nationwide Danish register study.

Schwensen CF, Brandt F, Hegedüs L, Brix TH.

Eur J Endocrinol. 2017 Jun;176(6):669-676. doi: 10.1530/EJE-16-0954. Epub 2017 Mar 3.

PMID:
28258132
5.

Excess mortality in hyperthyroidism: the influence of preexisting comorbidity and genetic confounding: a danish nationwide register-based cohort study of twins and singletons.

Brandt F, Almind D, Christensen K, Green A, Brix TH, Hegedüs L.

J Clin Endocrinol Metab. 2012 Nov;97(11):4123-9. doi: 10.1210/jc.2012-2268. Epub 2012 Aug 28.

6.

Hyperthyroidism is associated with work disability and loss of labour market income. A Danish register-based study in singletons and disease-discordant twin pairs.

Brandt F, Thvilum M, Hegedüs L, Brix TH.

Eur J Endocrinol. 2015 Nov;173(5):595-602. doi: 10.1530/EJE-15-0306. Epub 2015 Sep 24.

7.

Relationship between the number and impact of stressful life events and the onset of Graves' disease and toxic nodular goitre.

Matos-Santos A, Nobre EL, Costa JG, Nogueira PJ, Macedo A, Galvão-Teles A, de Castro JJ.

Clin Endocrinol (Oxf). 2001 Jul;55(1):15-9.

PMID:
11453947
8.

Decreased birth weight, length, and head circumference in children born by women years after treatment for hyperthyroidism.

Ohrling H, Törring O, Yin L, Iliadou AN, Tullgren O, Abraham-Nordling M, Wallin G, Hall P, Lönn S.

J Clin Endocrinol Metab. 2014 Sep;99(9):3217-23. doi: 10.1210/jc.2014-1168. Epub 2014 May 30.

PMID:
24878049
9.

Iodine-131 given for therapeutic purposes modulates differently interferon-gamma-inducible alpha-chemokine CXCL10 serum levels in patients with active Graves' disease or toxic nodular goiter.

Antonelli A, Rotondi M, Fallahi P, Grosso M, Boni G, Ferrari SM, Romagnani P, Serio M, Mariani G, Ferrannini E.

J Clin Endocrinol Metab. 2007 Apr;92(4):1485-90. Epub 2007 Jan 23.

PMID:
17244787
10.

Improved quality of life in hyperthyroidism patients after surgery.

Bukvic B, Zivaljevic V, Sipetic S, Diklic A, Tausanovic K, Stojanovic D, Stevanovic D, Paunovic I.

J Surg Res. 2015 Feb;193(2):724-30. doi: 10.1016/j.jss.2014.07.061. Epub 2014 Jul 30.

PMID:
25167783
11.

Death by Suicide in Graves' Disease and Graves' Orbitopathy: A Nationwide Danish Register Study.

Ferløv-Schwensen C, Brix TH, Hegedüs L.

Thyroid. 2017 Dec;27(12):1475-1480. doi: 10.1089/thy.2017.0365.

PMID:
29084476
12.

Smoking as a risk factor for Graves' disease, toxic nodular goiter, and autoimmune hypothyroidism.

Vestergaard P, Rejnmark L, Weeke J, Hoeck HC, Nielsen HK, Rungby J, Laurberg P, Mosekilde L.

Thyroid. 2002 Jan;12(1):69-75.

PMID:
11838733
13.

HLA antigens in Greek patients with thyrotoxicosis (Graves' disease and toxic nodular goiter).

Papasteriades C, Alevizaki-Harhalaki MN, Economidou J, Ikkos DG.

J Endocrinol Invest. 1984 Aug;7(4):283-6.

PMID:
6594386
14.

Th1 and Th2 serum cytokine profiles characterize patients with Hashimoto's thyroiditis (Th1) and Graves' disease (Th2).

Phenekos C, Vryonidou A, Gritzapis AD, Baxevanis CN, Goula M, Papamichail M.

Neuroimmunomodulation. 2004;11(4):209-13.

PMID:
15249726
15.

Effect of stressful life events on the initiation of graves' disease.

Topcu CB, Celik O, Tasan E.

Int J Psychiatry Clin Pract. 2012 Oct;16(4):307-11. doi: 10.3109/13651501.2011.631016. Epub 2011 Dec 5.

PMID:
22136213
16.

Clinical outcome of radioiodine treatment of hyperthyroidism: a follow-up study.

Berg G, Michanek A, Holmberg E, Nyström E.

J Intern Med. 1996 Feb;239(2):165-71.

PMID:
8568485
17.

Increase of interferon-gamma-inducible CXC chemokine CXCL10 serum levels in patients with active Graves' disease, and modulation by methimazole therapy.

Antonelli A, Rotondi M, Fallahi P, Romagnani P, Ferrari SM, Barani L, Ferrannini E, Serio M.

Clin Endocrinol (Oxf). 2006 Feb;64(2):189-95.

PMID:
16430719
18.

Serum levels of the carboxy-terminal cross-linked telopeptide of type I collagen and laminin are elevated in Graves' disease but not in toxic nodular goiter.

Wenisch C, Bankl HC, Schönthal E, Myskiw D, Presterl E, Rumpold H, Graninger W.

Clin Immunol Immunopathol. 1995 Jun;75(3):225-30.

PMID:
7768039
19.

Iodine-131 treatment of hyperthyroidism: significance of effective half-life measurements.

Berg GE, Michanek AM, Holmberg EC, Fink M.

J Nucl Med. 1996 Feb;37(2):228-32.

20.

Nationwide Assessment of Cause-Specific Mortality in Patients with Rosacea: A Cohort Study in Denmark.

Egeberg A, Fowler JF Jr, Gislason GH, Thyssen JP.

Am J Clin Dermatol. 2016 Dec;17(6):673-679.

PMID:
27480418

Supplemental Content

Support Center